ClinicalTrials.gg
CompletedNCT00649415Updated Dec 5, 2018

A Double Blind, Double Dummy, Randomized, Comparative Study Of The Efficacy And Safety Of Valdecoxib 40 Mg Twice Daily, As Needed In The First Menstrual Cycle Day And Then Once A Day, And Piroxicam 40 Mg Once A Day In The Treatment Of Patients With Primary Dysmenorrhea

A Phase 4 interventional study of piroxicam and valdecoxib in Dysmenorrhea, sponsored by Pfizer. Completed at 10 sites in Brazil. Open to female participants aged 18 Years to 44 Years. Per ClinicalTrials.gov, last updated 2018-12-05.

Sponsored by Pfizer · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
154
Allocation
Randomized
Ages
18 Years to 44 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies in Dysmenorrhea with a site in Brazil — 2 open to participants now, 2 under way, 1 of them phase 3. Dysmenorrhea · Brazil.

Started
2003
the only one that year
Phase 4
2 of 10
none open now
Registered
1st of 10
by date
Lead sponsor
1 of 10
Pfizer

Among the 10 studies in Dysmenorrhea with a site in Brazil, this one is the only one that started in 2003, is one of 2 in phase 4, and was the 1st registered.

Dysmenorrhea

432 studies on the registry are indexed under Dysmenorrhea; 109 are open to participants now.

Browse Dysmenorrhea studies →

Open to participants now

2 of the 10 studies in Dysmenorrhea with a site in Brazil are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Brazil have not opened yet or have stopped. Only those recruiting at a site in Brazil →

Who these studies take

Of the 59 Dysmenorrhea studies recruiting now, 7 (12%) set no upper age limit and 51 (86%) stop at 75 or younger; 11 take children under 18; 20 take healthy volunteers.

This study: 18 Years to 44 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Dysmenorrhea with a site in Brazil, or all of them as a file.
02

Study summary

To compare the analgesic efficacy, safety, and tolerability of valdecoxib versus piroxicam in subjects with moderate to severe menstrual cramping pain associated with primary dysmenorrhea.

03

Conditions studied

  • Dysmenorrhea

Browse trials for

04

Who can participate

Ages eligible
18 Years to 44 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • History of primary dysmenorrhea with moderate to severe menstrual cramping pain for which the patient took analgesic medication for at least three of six previous menstrual cycles before enrollment
  • Subjects were to have been in good health and were to have had a complete physical exam (including a pap smear and an endovaginal or pelvic ultrasound, unless the subject had had these examinations performed within 6 months prior to the Screening Visit and the results were normal) prior to inclusion

Exclusion criteria

Exclusion Criteria:

  • Subjects who were pregnant, lactating, breastfeeding or not using adequate methods of
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
154 participants (actual)

Study arms

  • Active comparator
    Arm 1

    Drug: piroxicam

  • Active comparator
    Arm 2

    Drug: valdecoxib

Interventions

  • piroxicam 40 mg capsule QD for up to the first 3 days of the menstrual cycle

  • valdecoxib 40 mg capsule twice a day (BID), taken as required, on the first day of treatment in the menstrual cycle followed by oral valdecoxib 40 mg once a day (QD) for up to the first 3 days of the menstural cycle

06

What researchers measure

Primary outcomes

  1. Total pain relief were calculated as the summed weighted pain releif scores

    Time frame: 8 hours

Secondary outcomes

  1. adverse events

    Time frame: approximately 5 days after treated cycle

  2. laboratory analyses

    Time frame: screening

  3. Subjects' global evaluation of the study drug

    Time frame: 8 hours and 72 hours

  4. Summed pain intensity difference

    Time frame: 8 hours

  5. Percent of subjects who took rescue medication

    Time frame: 72 hours

  6. Percent of subjects who took the second dose of study medication

    Time frame: 72 hours

07

Study locations

10 sites
  • Pfizer Investigational Site
    Salvador, Bahia, Brazil
  • Pfizer Investigational Site
    Goiania, Goias, Brazil
  • Pfizer Investigational Site
    Belo Horizonte, Minas Gerais 30130-100, Brazil
  • Pfizer Investigational Site
    Belo Horizonte, Minas Gerais 30130-110, Brazil
  • Pfizer Investigational Site
    Porto Alegre, Rio Grande Do Sul 90610-000, Brazil
  • Pfizer Investigational Site
    Rio De Janeiro, RJ 20551-030, Brazil
  • Pfizer Investigational Site
    Porto Alegre, RS, Brazil
  • Pfizer Investigational Site
    São Paulo, SP, Brazil
  • Pfizer Investigational Site
    Sao Paulo, Brazil
  • Pfizer Investigational Site
    São Paulo, 04062-003, Brazil
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2003 and a completion of Jul 2003. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 28, 2008
First posted
Apr 1, 2008
Start
Jan 2003
CompletionActual
Jul 2003
Last update
Dec 5, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 5, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00649415
Lead sponsor
Pfizer
First posted
Apr 1, 2008
Start date
Jan 2003
Completion
Jul 2003
Last update
Dec 5, 2018

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Piroxicam · Valdecoxib

Start the discussion